Document Detail


Chios mastic treatment of patients with active Crohn's disease.
MedLine Citation:
PMID:  17278198     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To evaluate the effectiveness of mastic administration on the clinical course and plasma inflammatory mediators of patients with active Crohn's disease (CD).
METHODS: This pilot study was conducted in patients with established mild to moderately active CD, attending the outpatient clinics of the hospital, and in healthy controls. Ten patients and 8 controls were recruited for a 4-wk treatment with mastic caps (6 caps/d, 0.37 g/cap). All patients successfully completed the protocol. CD Activity Index (CDAI), Nutritional Risk Index (NRI), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemotactic protein-1 (MCP-1), and total antioxidant potential (TAP) were evaluated in the plasma at baseline and at the end of the treatment period. Results were expressed as mean values +/- SE and P < 0.05 was considered to indicate statistical significance.
RESULTS: Patients exhibited significant reduction of CDAI (222.9 +/- 18.7 vs 136.3 +/- 12.3, P = 0.05) as compared to pretreament values. Plasma IL-6 was significantly decreased (21.2 +/- 9.3 pg/mL vs 7.2 +/- 2.8 pg/ mL, P = 0.027), and so did CRP (40.3 +/- 13.1 mg/mL vs 19.7 +/- 5.5, P = 0.028). TAP was significantly increased (0.15 +/- 0.09 vs 0.57 +/- 0.15 mmol/L uric acid, P = 0.036). No patient or control exhibited any kind of side effects.
CONCLUSION: The results suggest that mastic significantly decreased the activity index and the plasma levels of IL-6 and CRP in patients with mildly to moderately active CD. Further double-blind, placebo-controlled studies in a larger number of patients are required to clarify the role of this natural product in the treatment of patients with CD.
Authors:
Andriana C Kaliora; Maria G Stathopoulou; John K Triantafillidis; George V Z Dedoussis; Nikolaos K Andrikopoulos
Related Documents :
20572418 - Endothelial function in patients with post-cpap residual sleepiness.
12627008 - Correlation between transcranial interleukin-6 gradient and outcome in patients with ac...
16859588 - Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell art...
11277348 - C-reactive protein values and erythrocyte sedimentation rates after total hip and total...
21843538 - Neural correlates of the processing of self-referent emotional information in bulimia n...
9488068 - Transversely tubularized ileal segments for the mitrofanoff or malone antegrade colonic...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  13     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-05     Completed Date:  2007-03-27     Revised Date:  2014-09-07    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  748-53     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Aged
Crohn Disease / drug therapy*,  immunology
Female
Humans
Male
Middle Aged
Phytotherapy*
Pilot Projects
Pistacia*
Plant Preparations / administration & dosage*,  adverse effects
Remission Induction
Resins, Plant / administration & dosage*,  adverse effects
Treatment Outcome
Chemical
Reg. No./Substance:
0/Plant Preparations; 0/Resins, Plant; 61789-92-2/gum mastic
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of age on outcome of total laparoscopic fundoplication for gastroesophageal reflux disease...
Next Document:  Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cy...